Does Wegovy Actually Shrink Your Stomach?

What the STEP 1 trial actually showed about fullness and eating behaviour

The clearest picture comes from the STEP 1 study, published in the New England Journal of Medicine. Participants reduced their body weight by roughly 15% over 68 weeks, not because their stomach shrank, but because semaglutide changed the hormonal environment that governs appetite. Hunger fell. Portion sizes shrank naturally. Cravings for calorie-dense food softened. These are measurable behavioural changes that show up in controlled trials, not just patient reports.

The mechanism is specific. GLP-1, glucagon-like peptide 1, is a hormone the gut releases when food arrives. Semaglutide is a synthetic version that stays active in the body far longer than the natural form, giving the brain a sustained signal that eating is complete. Receptors in the hypothalamus respond by turning the hunger dial down. Receptors in the vagus nerve slow how quickly the stomach empties. Both effects together mean you eat less, feel full earlier, and think about food less often throughout the day.

The physical structure of the stomach is unchanged throughout. A common misconception worth naming plainly is that GLP-1 medicines work like bariatric surgery, mechanically reducing stomach capacity. They do not. The stomach remains exactly as it was; it is the chemistry around eating that shifts. What Wegovy actually does to your stomach goes into this mechanism in more depth if you want the full picture.

Why gastric emptying slows, and what that means day to day

When food lingers in the stomach longer than usual, a few things happen. Stretch receptors in the stomach wall stay activated for longer, sending continued fullness signals to the brain. Blood glucose rises more gradually, which reduces the sharp post-meal energy dips that often trigger snacking. And the window between feeling satisfied and feeling hungry again widens considerably.

Practically, people on Wegovy often report that meals feel complete after noticeably smaller amounts of food. Some find that foods they previously ate freely now feel heavy or sit uncomfortably. This is the gastric emptying effect made tangible. For a detailed look at how this plays out specifically, the guide to semaglutide's activity in the stomach covers the physiology step by step.

The slowing of gastric emptying is also what drives the most common side effects. Nausea, indigestion and a sense of bloating are all natural consequences of food spending more time in the stomach. These effects are typically most noticeable in the first few weeks or after each dose increase, and most people find they ease as the body adjusts. The overview of stomach pain on Wegovy explains which symptoms are expected and which warrant medical advice. If your semaglutide side effects feel more like an acute illness, there is also guidance specifically on stomach flu-like symptoms during treatment.

Who Wegovy is licensed for, and the clinical process behind that

Wegovy is licensed in the UK for adults with a BMI of 30 or above, or 27 and above alongside at least one weight-related condition such as high blood pressure, high cholesterol or type 2 diabetes. Lower BMI thresholds may apply for some ethnic backgrounds under UK guidance. NICE's appraisal of semaglutide sets additional criteria for NHS access via specialist weight management services; on the private route, the SmPC eligibility criteria apply and a prescriber makes the individual assessment.

As the NHS medicines page for semaglutide sets out, these are prescription-only medicines assessed on the full clinical picture, not just a BMI number. A prescriber considers your medical history, any other medicines you take, and whether the expected benefit outweighs any risks for you specifically. Wegovy is not recommended in pregnancy, whilst breastfeeding, or for anyone under 18.

If you are already on treatment and noticing persistent stomach discomfort, it is always worth raising this with your prescriber rather than waiting for the next scheduled review. That is exactly what ongoing clinical support is there for. For a broader look at weight management options, the weight loss treatment overview sets out what is currently licensed in the UK and how each option works.